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Edited by Felix WielandAbstract The degeneration of neurons in disorders such as Alz-
heimer’s disease has an immediate consequence, the release of
intracellular proteins into the extracellular space. One of these
proteins, tau, has proven to be toxic when added to cultured neu-
ronal cells. This toxicity varies according to the degree of protein
aggregation. The addition of tau to cultured neuroblastoma cells
provoked an increase in the levels of intracellular calcium, which
is followed by cell death. We suggest that this phenomenon may
be mediated by the interaction of tau with muscarinic receptors,
which promotes the liberation of calcium from intracellular
stores.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Alzheimer’s disease (AD) is characterized by the appearance
in the brain of two aberrant structures: extracellular senile pla-
ques and intracellular neuroﬁbrillary tangles (NFT: [1]). While
senile plaques are composed of the beta amyloid peptide [2]
(for a review, see: [3,4]), the neuroﬁbrillary tangles contain
paired helical ﬁlaments (PHF) that are formed of hyperphos-
phorylated isoforms of the microtubule associated protein
tau [5] (for a review, see: [6]). The distribution of senile plaques
in the brain varies widely, not only between brain regions but
also from one individual to another one [7]. In contrast, the
formation of neuroﬁbrillary tangles follows a reproducible pat-
tern, whereby they ﬁrst appear in the entorhinal cortex (EC)
and from there, the pathology spreads to surrounding areas
like the hippocampus [7]. Indeed, the progress of the formation
of tangles correlates with the progress of the disease, that can
also be followed by examining the increase of tau phosphoryl-
ation [8]. In damaged regions, like the hippocampus, there is
an inverse relationship between the number of extracellular
tangles and the number of surviving cells [9–11]. This suggests
that the neurons, which contain ﬁbrillar lesions and that
degenerate, might release the NFT into the extracellular envi-
ronment [12]. Similarly, upon neuron death, other intracellularAbbreviations:Ab, beta amyloid peptide; AD, Alzheimer’s disease; EC,
entorhinal cortex; MT, microtubule; NFT, neuroﬁbrillary tangles;
PHF, paired helical ﬁlaments
*Corresponding author. Fax: +34 914974799.
E-mail address: javila@cbm.uam.es (J. Avila).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
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and subsequently in the cerebrospinal ﬂuid [13]. It is not abso-
lutely clear whether intracellular ﬁbrillar tau is toxic to a
neuron, since the degeneration of a neuron containing neuro-
ﬁbrillary lesions can take a long time [14], even though tau
aggregates are sticky polymers that may sequester diﬀerent
proteins needed for correct cell function [15]. Thus, intracellu-
lar NFT toxicity remains under discussion [16–18]. Addition-
ally, the way in which the tau pathology spreads remains
unclear [7]. One possible explanation of how the tau pathology
could extend in the brain of AD patients following such a
reproducible pattern, is that extracellular NFT, or other com-
pounds released by degenerating neuron, may accumulate in
the extracellular space and they could be toxic to the surround-
ing undamaged cells [19]. These toxic compounds could act in
a similar way as the extracellular beta amyloid peptide. In this
study, we have tested whether extracellular tau or PHF tau are
toxic to neuronal cells.2. Materials and methods
2.1. Tau samples nomenclature
Diﬀerent tau protein samples will be described in the text as follows:
the recombinant tau protein isoform containing 2 N-terminal inserts
and 4 microtubule binding repeats (tau 42 [20]) is named as tau; the
same isoform of tau bearing the mutations G272V, P301L and
R406W [21] as tauvlw;; the tau fragment containing the ﬁrst and third
microtubule binding repeats as tau 2R; the tau 42 isoform lacking res-
idues 306–311 as tau D306–311; and the tau peptide containing residues
306–311, as tau 306–311.
2.2. Protein puriﬁcation
The recombinant tau protein isoform (tau 42) containing 2 N-termi-
nal inserts and 4 microtubule binding repeats [20]; the same isoform of
tau bearing the mutations G272V, P301L and R406W (tauvlw: [21]);
the tau fragment 2R containing the ﬁrst and third microtubule binding
repeats; and the tau 42 isoform lacking residues 306–311 (tau D306–
311) were isolated as described previously [22]. Phosphorylated iso-
forms of tau 42 and tauvlw were obtained from an insect cell culture
infected with baculovirus expressing these tau proteins [23]. For some
experiments, these proteins were dephosphorylated by phosphatase k
[24] according to the manufacturer’s recommendations (New England
Biolabs, Boston, MA). Tau peptide containing residues 306–311 (tau
306–311) and the Ab peptide (25–35) were obtained from Neo-MPS
(Strasbourg, France). The isolated proteins were fractionated by gel
electrophoresis and stained with Coomassie blue. The tau protein con-
tent was determined by the BCA assay, at 37 C. Once the protein con-
tent was determined, increasing amounts of this protein were western
blotted and their reaction with Ab 7.51 was tested. This reaction of
Ab 7.51 was also used as a reference to calculate the protein concentra-
tion of other tau preparations.
Filtration chromatography analyses of diﬀerent tau samples were
performed on a Sepharose CL6B column [25] equilibrated in a buﬀer
containing 0.1 M morpholine ethane sulfonate (MES) pH 6.4, 2 mMblished by Elsevier B.V. All rights reserved.
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of hexaﬂuorisopropanol was carried out as indicated previously for
other proteins [26]. The aggregation of tau-heparin ﬁlaments was also
carried out as indicated previously [22], while Ab peptide aggregation
and the determination of toxicity were carried out as described in [27].
2.3. Antibodies
The antibodies used to detect unpolymerized tau were Ab7.51 (a
kind gift of Dr. Wischik, UK) [28], and the 12E8 antibody (Athena
Laboratories) which recognizes tau phosphorylated at serine 262 (a
kind gift from Dr. Seubert [29]). The antibodies used to detect aggre-
gated tau were PHF-1 and Alz-50 (a kind gift from Dr. Davies
[30,31]). Antibodies to characterize the b-tubulin subunit were ob-
tained from Sigma (St. Louis, MO, USA).
2.4. Paired helical ﬁlament isolation
Paired helical ﬁlaments were isolated as described previously [31].
Isolated PHF and other tau ﬁlaments were characterized by electron
microscopy [32].
2.5. Cell culture
SH-SY5Y human neuroblastoma cells were grown in Dulbecco’s
modiﬁed Eagle medium (DMEM) supplemented with 10% fetal bovine
serum. To assay viability, 1 · 105 cells were seeded on glass coverslips
in well plates and after 24 h incubation, they were exposed to diﬀerent
amounts of tau (or its variants) in soluble or aggregated form, for 24 or
48 h. Thirty minutes before performing the experiment, the cells were
incubated with 1 mM calcein-AM and 2 lM propidium iodide were
Molecular Probes (Eugene, OR). Cell viability was measured by di-
rectly counting of the cells labeled with propidium iodide (red ﬂuores-
cence, dead cells) and calcein-AM (green ﬂuorescence, live cells). Four
samples were tested under each condition. We also used a lactatodehy-
drogenase (LDH) kit (Roche diagnostics, Mannheim, Germany) to test
cell viability. Control cells were incubated with the same volume of
buﬀer in each case.
2.6. Calcium dependent ﬂuorescence signal analysis – image acquisition
and analysis of the Ca2+ response in SH-SY5YS cells
SH-SY5YS cells cultured on coverslips were washed with perfusion
buﬀer (122 mM NaCl, 3.1 mM KCl, 0.4 mM KH2PO4, 5 mM Na-
HCO3, 1.2 mM MgSO4, 10 mM glucose and 20 mM N-Tris(hydroxy-
methyl)methyl-2-aminoethanesulfonic acid (TES) buﬀer, pH 7.4), and
they were loaded with FURA-2AM (7.5 lM) for 45 min at 37 C.
This period facilitated the intracellular hydrolysis of the FURA-
2AM. Subsequently, the coverslips were washed with fresh medium
and mounted in a superfusion chamber in a NIKON Eclipse TE-
2000 microscope. In all experiments the cells were superfused ﬁrst
at 1.2 ml/min with perfusion media and then, with 70 lM ACh in
order to establish the functional cell status. When unpolymerized
or oligo and polymerized tau proteins were assayed, the perfusion
system was stopped. When the experiments were performed with cho-
linergic antagonists, hexamentonium (10 lM) and atropine (100 lM),
the cells were superfused for 2 min before applying ACh or Tau.
Incubation with the non-selective voltage dependent calcium channel
blocker was carried out by superfusing for 10 min with CdCl2
(50 lM) before the addition of Tau. At the end of each experiment,
70 lM ACh pulses were applied to conﬁrm the viability of the cells
under study. Cells were visualized using a Nikon ·40 S Fluor 0.5–
1.3 oil lens. The wavelength of the incoming light was ﬁltered to
340 nm and 380 nm with the aid of a monochromator (10 nm band-
width, Optoscan monocromator, Cairin). These wavelengths corre-
sponded to the ﬂuorescence peaks of Ca2+-saturated and Ca2+-free
FURA-2 solutions. The 12-bit images were acquired with an
ORCA-ER C 47 42–98 CCD camera from Hamamatsu (Hamamatsu
City, Japan) controlled by Metaﬂuor 6.3r6 PC software (Universal
Imaging Corp., Cambridge, UK). The exposure time was 150 ms
for each wavelength and the changing time <5 ms. The images were
acquired continuously and buﬀered in a fast SCSI disk. The time
course data represent the average light intensity in a small elliptical
region inside each cell. The background and autoﬂuorescence compo-
nents were subtracted at each wavelength, and the 340 over 380 nm
ratio was calibrated into [Ca2+]i values using Grynkiewicz’s equation
[33]. The Rmax, Rmin and b parameters were calculated from the
spectra of small droplets of fura-2 in Ca2+-saturated and Ca2+-freesolutions (100 mM KCl, 10 mM NaCl, 1 mM MgCl2, 10 mM Tris,
10 mM MOPS and 100 lM fura-2. Ca2+-free: plus 2 mM EGTA.
Ca2+-saturated: plus 2 mM CaCl2) [34,35]. The in vitro Rmax and
Rmin were corrected for the diﬀerences with the cytosolic environment
using the procedure described by Poenie [36,37].
2.7. Statistical analysis
Data correspond to mean values ± S.D. The statistical signiﬁcance
of the results was measured by Student’s t-test. Diﬀerences were con-
sidered statistically signiﬁcant at P 6 0.05.3. Results
3.1. Characterization of soluble and aggregated tau protein
In order to test the possible toxicity of tau on cultured
neuroblastoma cells, we ﬁrst isolated and characterized tau
in its soluble form or when polymerized into PHF. We found
that the recombinant tau isolated protein existed in part in an
oligomerized form, as indicated by chromatography ﬁltration
on Sepharose CL6B (Fig. 1A), and thus it behaves like the na-
tive tau protein [25]. When the tau protein was incubated in
the presence of hexaﬂuorisopropanol, the oligomers found
were similar but not identical to those identiﬁed previously
(Fig. 1B). Indeed, the oligomers generated under these condi-
tions where able to bind to Ab Alz-50 (not shown). In con-
trast, there were fewer oligomers formed when a tau variant
lacking residues 306–311 was analyzed by gel ﬁltration
(Fig. 1C). Nevertheless, the 2R variant also elutes in aggre-
gated form (Fig. 1D). The elution volume of the tau oligomers
and monomers, together with those of two molecular weight
markers, catalase and bovine serum albumin is shown in
Fig. 1E.
3.2. Tau promotes death in cultured cells
As previously indicated, neurons containing ﬁbrillar lesions
may degenerate and liberate NFT (PHF) and other intracellu-
lar components into the extracellular space as ghost tangles or
as extracellular proteins. Thus, we tested the eﬀects of exposing
cultured cells to PHF. We found that the addition of increas-
ing amounts of PHF was indeed toxic to the cells and pro-
moted a slight increase in cell death (Fig. 2A). Since the
main component of PHF is the tau protein, we also examined
the eﬀect of this protein in its unaggregated form. Exposing
cells to isolated disaggregated tau produced a further increase
in cell death when compared to that observed in control cells
that were not exposed to tau protein (Fig. 2A). The tau variant
lacking residues 306–311 (tau D306–311) was also tested in
these assays (Fig. 2A). Exposure of the cells to this tau variant
produced an increase in cell death when compared with the
previous tau preparations was analyzed. Finally, the eﬀects
of the tau 2R variant and that of tau peptide containing
residues 306–311 were tested (Fig. 2A). It has been shown
previously that the toxic eﬀects of unpolymerized and polymer-
ized tau on cell death diﬀer. Indeed, when tau protein (tau 2R)
was mixed with heparin to promote its aggregation [22,38], a
decrease in its toxicity was observed (see inset Fig. 2B(f)).
Moreover, tau toxicity clearly increased over time as seen when
the cells were exposed to the diﬀerent tau variants for 24 or
48 h (Fig. 2B). This was similar to the time dependent toxicity
of the Ab oligomer used as a positive control (Fig. 2B(e)).
Also, in the ﬁgure has been included a negative control, albu-
min (see inset of Fig. 2B(e)).
Fig. 1. Size exclusion chromatography of tau samples. Filtration chromatography analyses were performed on a Sepharose CL6B column
equilibrated in a buﬀer containing 0.1 mM (MES) pH 6.4, 2 mM MgCl2, 1 mM EGTA. The elution proﬁles for: (A) recombinant tau, mainly, with
two elution peaks (arrows). (B) Hexaﬂuoroisopropanol induced tau oligomers, (C) tau D306–311, and (D) tau 2R, are shown. In (E) the elution
fractions for the molecular weight markers catalase (240 kDa), bovine serum albumin (68 kDa) and cytochrome c (12 kDa) are shown, together with
those of tau oligomers (180 kDa) and tau monomers (47 kDa). Insets in the ﬁgures indicate the electrophoretic mobility, in denaturing conditions, of
the diﬀerent used tau fractions (arrows), together with the electrophoretic mobility of molecular weight markers.
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Fig. 2. Toxic eﬀect of tau samples on SH-SY5Y neuroblastoma cells. Cultured SH-SY5Y neuroblastoma cells (see Section 2) were incubated with
increasing concentrations of tau preparations. (A) The eﬀect of increasing tau concentrations on cell viability is shown: Recombinant tau (n), tau
D306–311 (}), tau 2R (D), PHF-tau (s) and tau peptide containing residues 306–311 (r). (B) The eﬀect of tau at a concentration of 5 lM on cell
viability was examined after 24 and 48 h. (a) Recombinant tau, (b) tau D306–311, (c) tau peptide containing residues 306–311, (d) PHF-tau, (e) Ab25–
35 polymers (as a positive control, at 20 lM). In the inset the results obtained upon addition of serum albumin at 0.1 mM (negative control), (f) tau
2R. In the inset the results for tau 2R, previously incubated with heparin, are shown. The statistical signiﬁcance of the results was measured by
Student’s t-test *P < 0.05 versus control cells at their respective incubation time in each case.
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We tested the eﬀect of phosphorylation on cell toxicity using
two tau variants: phosphorylated tau and that of tau bearing
mutations present in frontotemporal dementia with Parkinson-
ism associated to chromosome 17 (see Section 2). These tau
variants were ﬁrst characterized by gel electrophoresis and
Western blotting (Fig. 3A). When neuroblastoma cells were ex-
posed to these phosphorylated tau isoforms some diﬀerences
were observed when compared to that of the unmodiﬁed tau
isoforms (Fig. 3B). Although, only slight diﬀerences were
found, a lower toxicity was observed for phosphorylated tau
compared to unmodiﬁed tau. Nevertheless, both types of tau
isoforms are toxic. Again, the toxicity of these tau variants
augmented with exposure time (Fig. 3C).
3.4. Changes in the microtubule network of neuroblastoma cells
upon addition of tau
We further analyzed the eﬀect of tau proteins on the micro-
tubule network of cultured cells (Fig. 4). The number of assem-
bled microtubules visualized by immunoﬂuorescence appeared
to decrease in proportion to the increase in DAPI staining, an
eﬀect observed when chromatin condensation occurs prior to
cell death (Fig. 4). Since the decrease in microtubule stainingmay be due to a deregulation of calcium homeostasis in the cell
cytoplasm, we studied whether exposure to tau aﬀects the
intracellular calcium levels. A rise in intracellular calcium
levels could induce an increase in the activity of calcium
dependent enzymes like protein kinase C (PKC). Indeed, this
kinase phosphorylates serine 262 of the tau protein, a modiﬁ-
cation that can be identiﬁed by the recognition of this phos-
phoresidue with the 12E8 antibody [39]. Upon addition of
recombinant tau protein to neuroblastoma cells, an increase
in the phosphorylation of the endogenous tau at serine 262
was clearly observed (Fig. 4B).
3.5. Exposure to Tau deregulates calcium homeostasis
in neuroblastoma cells
Since intracellular calcium levels appeared to be aﬀected by
exposure of the neurons to tau (Fig. 4), we set out to further
test this phenomenon. We examined the eﬀect of adding the
previously characterized recombinant tau, tau D306–311 var-
iant, recombinant tau treated with hexaﬂuoroisopropanol and
PHF-tau, to FURA-2AM loaded SH-SY5Y neuroblastoma
cells. This cell line has been studied previously in order to test
the toxicity of Ab oligomers [24]. The mean calcium depen-
dent ﬂuorescence was measured in 20 cells exposed to tau
Fig. 3. Toxic eﬀect of tau variants on SH-SY5Y neuroblastoma cells. Cultured SH-SY5Y neuroblastoma cells (see Section 2) were incubated with
increasing concentrations of tau preparations, in unmodiﬁed or phosphorylated form, isolated from insect cells (overexpressing tau or the tauvlw
variant). These expressed tau are present in a hyperphosphorylated form [23]. To isolate them, in their unmodiﬁed form, the tau preparations were
incubated with phosphatase k. (A) Untreated or phosphatase treated tau samples were separated by gel electrophoresis, blotted onto nitrocellulose
membranes, and probed with the AT8 (which recognizes phosphotau) and T14 (which recognizes tau independent of its phosphorylation state)
antibodies. (B) The eﬀect of unmodiﬁed tau (j), phosphotau (m), unmodiﬁed tauvlw (h), phosphotauvlw (D) on cell viability is shown. (C) As in (B),
but the eﬀect of 5 lM tau on cell viability was tested at two diﬀerent times, 24 · h and 48 h. (a) tau, (b) tauvlw, (c) phosphotau, (d) phosphotauvlw.
The statistical signiﬁcance of the results was measured by Student’s t-test *P < 0.05 versus control cells at their respective incubation time in each
case.
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control ACh all augmented the FURA-2 signal with a peak
increase of DF/F = 3.2 ± 0.4 (S.E., Fig. 5A). While exposure
to tau treated with hexaﬂuoroisopropanol had a smaller ef-
fect, PHF-tau had no eﬀect at all on the intracellular calcium
levels.
3.6. A possible mechanism for tau-induced calcium deregulation
Questions still remain regarding the possible mechanism
underlying tau toxicity and the increase in cytoplasmic cal-cium. Several mechanisms might be responsible for the calcium
mobilization provoked by tau, including the inﬂux of calcium
through membrane channels. To test this possibility, we
assessed the eﬀect of tau proteins in the presence of 50 lM
cadmium, a non-speciﬁc blocker of many calcium-permeable
channels [40]. The presence of cadmium had no inﬂuence on
the alterations in the intracellular calcium signals induced by
tau (Fig. 5B(a)). The increase in cytoplasmic calcium provoked
by tau could also be due to the activation of cell surface recep-
tors coupled to calcium-inﬂux, such as the nicotinic receptor.
Fig. 4. Eﬀect of tau on microtubule organization. Cultured SH-SY5Y neuroblastoma cells were incubated with tau protein and the eﬀect on
microtubule network was tested by immunoﬂuorescence analysis. (A) Tau protein (1 lM) was added to SH-SY5Y cells in culture and the eﬀect on the
microtubule network is shown. An impoverished microtubule network was found in cells exposed to tau. In addition, an increase of DAPI staining
was observed in the cell nuclei. DAPI mainly binds to condensate chromatin (see mitotic cell in the control) and this increase in DAPI binding to
interphase nuclei may be indicative of cell damage in tau treated cells. (B) Western blot probed with an antibody recognising phosphotau (Ab 12E8)
on control and tau treated cell extracts. In the same experiment, the total amount of tau determined by its reaction with Ab 7.51 is shown.
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calcium liberation from intracellular stores that may be in-
duced by receptors such as those activated by muscarinic ago-
nists. Both nicotinic and muscarinic receptors are thought to
be expressed by SH-SY5Y cells [41–43]. However, the presence
of the nicotinic antagonist hexamethonium did not appear to
aﬀect the changes in calcium homeostasis induced by the diﬀer-ent tau variants (Fig. 5B(b)). However, in the presence of the
muscarinic antagonist atropine, we found a dramatic decrease
in the changes in intracellular calcium promoted by tau protein
(Fig. 5B(c)), even that observed when the cells were exposed to
the tau D306–311 variant. These experiments suggest that the
eﬀect of tau is mediated through muscarinic receptors present
in the neuroblastoma cells.
Fig. 5. Tau proteins elevate intracellular free calcium. Cultured SH-SY5Y were incubated with diﬀerent tau samples, and the changes in intracellular
calcium levels were analysed. (A) A time course of calcium dependent ﬂuorescence recorded from cells. FURA-2 loaded SH-SY5Y in response to
application of ACh (positive control) followed by that of either recombinant tau (1 lM), hexaﬂuoroisopropanol-induced tau oligomers (1 lM), tau
D306–311 (1 lM), or PHF-tau. The traces show the average responses from 20 cells. (B) (a) The changes in calcium-dependent ﬂuorescence were
recorded after the application of ACh in the absence or presence of 50 lMCd2+ to inhibit Calcium channels. Calcium changes were recorded after the
sequential application of ACh and recombinant tau in the presence of the same cation. The trace shows the average responses of 20 cells. (b) A similar
experiment to that shown in (a), but in this case hexamethonium (a nicotinic antagonist) was added to the cultures. (c) As in (b), but in this case
atropine (a muscarinic receptor antagonist) was addition along with ACh, recombinant tau, and tau D306–311.
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Fig. 6. Model for tau toxicity in neuroblastoma cells. Tau is mainly associated to microtubules inside neurons. Upon modiﬁcation(s), tau is no longer
bound to microtubules and depending on the protein concentration, it can aggregate or not. Upon neuron degeneration, tau accumulates in the
extracellular space and it becomes toxic to neighboring cells.
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The results we have obtained indicate initially that the tau
protein is toxic when added to neuroblastoma cells in culture.
This eﬀect could be relevant to the tau pathology related to
Alzheimer’s disease since in this disease, tau may accumulate
in the extracellular space as a consequence of neuronal death
[9]. In turn, this extracellular tau would serve to propagate
the cell death that is characteristic of this condition. The cause
of the neuronal death related with the tau pathology remains
unknown, although it commences in the EC and then spreads
to the neighboring neurons.
Under physiological conditions, the tau concentration in a
neuron has been calculated to be around 2 lM [44,45] and
essentially all tau protein (>95%) is tightly bound to the micro-
tubule (MT) network [45,46]. However, in pathological condi-
tions, tau could be modiﬁed by aberrant post-translational
events like hyperphosphorylation, truncation, deamidation,
etc. [47]. These modiﬁcations could lead to tau detaching from
MTs and accumulating in a free form. This free tau could pass
into the extracellular space when neurons degenerate, where it
would be free to diﬀuse. We could assume that the soma of a
neuron containing modiﬁed tau is a sphere with a radius of
10 lm, in which tau may be present at a concentration of
2 lM. Upon lysis of the neuron, tau will diﬀuse in every direc-
tion and as such, we can simulate its diﬀusion by considering
virtual spheres. In such a model, at a distance of about
15 lm from the soma of the damaged neurons, the concentra-
tion for extracellular tau will be around 130 nM. This concen-
tration was found to be at the limit of tau toxicity. In addition,
the distance between the soma of two neurons within a given
region, like the dentate gyrus or hippocampus, is about 3–
6 lm. Thus, at this distance tau will exert a toxic eﬀect on
the cells located close to the degenerating neurons. As indi-
cated, all tau protein is bound to MT in physiological condi-
tions. However, if in the pathological conditions the amount
of free tau exceeds that inside the cell, it may reach a critical
concentration that has been calculated by some authors to
be around 0.5 lM or higher (depending on the diﬀerent condi-
tions required for tau assembly [45]). At this concentration, the
tau protein will start to self aggregate and a change in extracel-
lular toxicity will take place. In fact we found a decrease in the
toxicity of PHF-tau compared to that of free tau. Tau toxicity
appears to be dependent on its interaction with muscarinic
receptors and it appears to involve an increase in intracellular
calcium. In turn, among other possible eﬀects the alterations in
intracellular calcium homeostasis may result in tau phosphor-
ylation, a modiﬁcation that could be related to the progress of
tau pathology in AD [8]. Tau phosphorylation will facilitatethe decrease of tau binding to microtubules, and it could occur
through the activation of calcium-dependent protein kinases
like PKC or CDK5 (through p25), known to phosphorylate
the tau protein at diﬀerent sites [47].
Thus, our current working hypothesis is summarized in the
model shown in Fig. 6. In this model the intracellular levels
of tau, that is not bound to MT in degenerating neurons,
may appear in the extracellular space (upon neurodegenera-
tion) where it will be toxic to those neighboring cells having
muscarinic receptors. These cells will degenerate and their
extracellular tau will be released and similarly exert a toxic
eﬀect in their surroundings.
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